Bozz,
Yes it is lots of $$$....and Sarepta's exon skipping drugs only serve 20% of the DMD population in the USA.
Greenfield market - and ANP will have ODD protection of 7 to 10 years exclusivity.
Sarepta is the most logical partner:
- They have PPMD on side
- They have Janet from FDA on side
- Clinical relationships throughout the US
- Extensive patient database
- Logistical footprint in the US for fast GoToMarket once FDA approves
- BIG investors on their register who will back them (Fidelity etc)
- THEY HAVE MOST TO LOSE....because their GT program is stuffed!
.
Where others have failed will Atl1102 succeed ?, page-630
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |